Legacy Wealth Managment LLC ID Buys New Shares in Lixte Biotechnology Holdings, Inc. $NMAD

Legacy Wealth Managment LLC ID acquired a new stake in Lixte Biotechnology Holdings, Inc. (NASDAQ:NMAD – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 600,669 shares of the company’s stock, valued at approximately $4,457,000. Lixte Biotechnology accounts for approximately 2.0% of Legacy Wealth Managment LLC ID’s investment portfolio, making the stock its 13th largest position.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Equitable Holdings Inc. acquired a new position in Lixte Biotechnology in the 2nd quarter worth approximately $74,000. Axxcess Wealth Management LLC acquired a new stake in Lixte Biotechnology during the 4th quarter valued at approximately $54,000. XTX Topco Ltd purchased a new stake in shares of Lixte Biotechnology in the 4th quarter valued at $57,000. FNY Investment Advisers LLC purchased a new stake in shares of Lixte Biotechnology in the 2nd quarter valued at $330,000. Finally, Geode Capital Management LLC increased its stake in shares of Lixte Biotechnology by 25.9% in the fourth quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after acquiring an additional 10,722 shares during the period. Institutional investors and hedge funds own 5.10% of the company’s stock.

Get Lixte Biotechnology alerts:

Lixte Biotechnology Trading Down 1.6%

Shares of NMAD stock opened at $3.65 on Friday. Lixte Biotechnology Holdings, Inc. has a twelve month low of $2.36 and a twelve month high of $8.38. The stock has a market cap of $58.77 million, a P/E ratio of -3.65 and a beta of 1.30. The stock has a 50 day moving average of $6.56 and a 200 day moving average of $5.10.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on NMAD shares. Wall Street Zen cut shares of Lixte Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings lowered shares of Lixte Biotechnology from a “sell (e+)” rating to a “sell (e)” rating in a report on Friday, August 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Get Our Latest Stock Report on Lixte Biotechnology

Lixte Biotechnology Company Profile

(Free Report)

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.

Featured Articles

• Five stocks we like better than Lixte Biotechnology
• The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
• NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
• Dropping the Dough: Yum! Brands Strategically Trims the Fat
• These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern

Want to see what other hedge funds are holding NMAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lixte Biotechnology Holdings, Inc. (NASDAQ:NMAD – Free Report).

Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.